aTyr Pharma, Inc.

aTyr is leveraging Physiocrine biology, a new and important area of human health, to develop first-in-class medicines to treat patients suffering from severe, rare diseases with significant unmet medical need. We successfully completed a Phase 1 clinical trial of Resolaris, our first development candidate from our discovery engine, and are currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with facioscapulohumeral muscular dystrophy, or FSHD, a severe, rare genetic myopathy with an immune component, for which there are currently no approved treatments. By leveraging our discovery engine and our knowledge of rare diseases, we aim to build a proprietary pipeline of novel product candidates with the potential to treat severe, rare diseases characterized by immune dysregulation. We were founded in 2005 by Paul Schimmel, Ph.D. and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute in San Diego, California. aTyr is publicly traded on Nasdaq under the symbol “LIFE”. We are currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with facioscapulohumeral muscular dystrophy, or FSHD, a severe, rare genetic myopathy with an immune component, for which there are currently no approved treatments. By leveraging our discovery engine and our knowledge of rare diseases, we aim to build a proprietary pipeline of novel product candidates with the potential to treat severe, rare diseases characterized by immune dysregulation. We understand disease never takes a day off and are relentlessly pursuing transformational science in order to make meaningful medicines for people with grave maladies where others fall short. Our potentially life-changing therapies are based on novel biological and therapeutic mechanisms that orchestrate important physiological processes in previously untapped ways. These shared principles galvanize our team of remarkable people who are working to achieve our mission and to provide positive outcomes for patients and other stakeholders throughout every aspect of our business.